 | • レポートコード：MRC2203A757 • 出版社/出版日：Mordor Intelligence / 2022年3月15日 • レポート形態：英文、PDF、126ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：バイオ |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料では、世界の動物モデル市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、動物種類別（マウス、鳥、魚、牛、その他）分析、技術別（CRISPR、胚性幹細胞注入、核移植、その他）分析、用途別（腫瘍、心臓血管、神経、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来の傾向などの項目を掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の動物モデル市場規模：動物種類別（マウス、鳥、魚、牛、その他） ・世界の動物モデル市場規模：技術別（CRISPR、胚性幹細胞注入、核移植、その他） ・世界の動物モデル市場規模：用途別（腫瘍、心臓血管、神経、その他） ・世界の動物モデル市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Biocytogen、Charles River、Envigo、...） ・市場機会・将来の傾向 |
The animal model market is expected to register a CAGR of 8.6% over the forecast period. The key contributors in the market growth are increasing number of clinical trials and increasing spending on these studies. As per the data of Europeans Medicine Agency, currently (2020) there are 37,293 clinical trials registered in Europe. Furthermore, according to the World Health Organization, in 2019, the number of registered trials were around 92% in South East Asia and around 66% in the Eastern Mediterranean region. Animal models are considered as a fundamental tool in clinical research studies for predicting the data for humans. It helps in determining the pharmacodynamic and pharmacokinectics of the drugs. Furthermore, according to the European Federation of Pharmaceutical Industries and Associations, the overall sales of pharmaceutical industry worldwide was recorded to be approximately 852,647 million USD.
Key Market Trends
Mice Segment is Expected to Exhibhit a Significant Market Growth in the Animal Model Market
The mice model segment is expected to show a significant growth in the market, primarily due to the increase in R&D activities in pharmaceutical industries. According to the European Federation of Pharmaceutical Industries and Associations, the overall sales of pharmaceutical industry worldwide was recorded to be approximately 852,647 million USD.
Mice and humans have around 95% of similarity in DNA and therefore it has wide range of applications such as in oncology studies, immunology and inflammation studies, central nervous system studies (anxiety and other disorders), cardiovascular studies, and diabetes studies. Thus, mice models are expected to have a larger demand in the market.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to be a dominant region in the Animal Model market owing to increasing investments and number of clinical trials. According to the clinical trials.gov, in 2019, around 293,321 studies were registered during the start of the year and around 32,523 at the end of year. Moreover, according to the Pharmaceutical Research & Manufacturers of America, in 2018, the R&D expenditure by biopharmaceutical companies were around 79.6 billion USD in the United States. Thus, the increasing number of clinical trials and heavy investments into these studies is expected to boost up the demand of pharmaceutical analytical testing market growth in the North America Region.
Competitive Landscape
Key players that are expected to be dominant in Animal Model market are Charles River, Envigo, Genoway, Harbour Biomed, Janvier Labs, Taconic Biosciences, The Jackson Laboratory, Trans Genic Inc., Hera Biolabs and Biocytogen
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Demand for Personalized Medicine
4.2.2 Increasing Number of Research & Development Activities
4.3 Market Restraints
4.3.1 Regulation for Ethical Use of Animals
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Animal Type
5.1.1 Mice
5.1.2 Birds
5.1.3 Fish
5.1.4 Cattles
5.1.5 Others
5.2 By Technology
5.2.1 CRISPR
5.2.2 Embryonic Stem Cell Injection
5.2.3 Nuclear Transfer
5.2.4 Others
5.3 By Application
5.3.1 Oncology
5.3.2 Cardiovascular
5.3.3 Neurology
5.3.4 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Biocytogen
6.1.2 Charles River
6.1.3 Envigo
6.1.4 Genoway
6.1.5 Harbour Biomed
6.1.6 Hera Biolabs
6.1.7 Janvier Labs
6.1.8 Taconic Biosciences
6.1.9 The Jackson Laboratory
6.1.10 Trans Genic Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS